Biosimilars in Inflammatory Bowel Disease
Over the past 2 decades, biological therapy with monoclonal antibodies targeting tumor necrosis factor-α has become a cornerstone of treatment of patients with inflammatory bowel disease. Although clinically effective, the biological therapies remain expensive, and their availability and utilization...
Saved in:
| Published in | The American journal of gastroenterology Vol. 116; no. 1; pp. 45 - 56 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
01.01.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Over the past 2 decades, biological therapy with monoclonal antibodies targeting tumor necrosis factor-α has become a cornerstone of treatment of patients with inflammatory bowel disease. Although clinically effective, the biological therapies remain expensive, and their availability and utilization have been at times limited due to their high costs. Biosimilars are biological products similar to but not identical to the original biological agent or "reference biologic," also called "originator biologic." It is hoped that the use of biosimilars might enable these agents to become more available and, thus, decrease further expenditures related to the use of the original reference agents such as infliximab and adalimumab. In this study, we review the currently available evidence and shortcomings of these data supporting the use of biosimilars for the treatment of patients with inflammatory bowel disease, including their efficacy and safety as related to initiating therapy with biosimilar agents or switching between reference and biosimilar biologic agents. |
|---|---|
| AbstractList | Over the past 2 decades, biological therapy with monoclonal antibodies targeting tumor necrosis factor-α has become a cornerstone of treatment of patients with inflammatory bowel disease. Although clinically effective, the biological therapies remain expensive, and their availability and utilization have been at times limited due to their high costs. Biosimilars are biological products similar to but not identical to the original biological agent or “reference biologic,” also called “originator biologic.” It is hoped that the use of biosimilars might enable these agents to become more available and, thus, decrease further expenditures related to the use of the original reference agents such as infliximab and adalimumab. In this study, we review the currently available evidence and shortcomings of these data supporting the use of biosimilars for the treatment of patients with inflammatory bowel disease, including their efficacy and safety as related to initiating therapy with biosimilar agents or switching between reference and biosimilar biologic agents. |
| Author | Buchner, Anna M Schneider, Yecheskel Lichtenstein, Gary R |
| Author_xml | – sequence: 1 givenname: Anna M surname: Buchner fullname: Buchner, Anna M organization: Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA – sequence: 2 givenname: Yecheskel surname: Schneider fullname: Schneider, Yecheskel – sequence: 3 givenname: Gary R surname: Lichtenstein fullname: Lichtenstein, Gary R |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33110013$$D View this record in MEDLINE/PubMed |
| BookMark | eNpdkEtPwzAQhC1URB_wE0CRuMAhxY534-RIy6tSJS5wthzXRqmSuNiNUP89hhaE2MtqV9-MRjMmg851hpBzRqcMOC1v1PptSv9OAXBERgxFltIM2ICM4jNLy0zQIRmHsKaUYSbwhAw5ZyxefESuZ7ULdVs3yoek7pJFZxvVtmrr_C6ZuQ_TJHd1MCqYU3JsVRPM2WFPyOvD_cv8KV0-Py7mt8tUA-XbtGCa5xywWNlcFVgBUsuosAIt12XBQKgcbA5VhVDZcqXFV3CBqMFilWs-IVd73413770JW9nWQZumUZ1xfZAZIDLBKCsjevkPXbvedzGdzJAKwLLMIVK4p7R3IXhj5cbXrfI7yaj87lLGLuX_LqPu4uDeV61Z_ap-yuOf_WxuEA |
| CitedBy_id | crossref_primary_10_1093_ibd_izac048 crossref_primary_10_1093_ecco_jcc_jjac013 crossref_primary_10_1016_S2468_1253_23_00003_1 crossref_primary_10_1080_14712598_2023_2203812 crossref_primary_10_1093_crocol_otab022 crossref_primary_10_1186_s13020_022_00633_4 crossref_primary_10_36502_2021_asjpch_6163 crossref_primary_10_1016_j_ejps_2023_106647 crossref_primary_10_1111_jgh_16202 crossref_primary_10_1007_s43441_022_00473_2 crossref_primary_10_14309_ajg_0000000000002461 |
| Cites_doi | 10.1136/annrheumdis-2012-203091 10.1016/j.cgh.2018.12.036 10.1016/S0140-6736(17)30068-5 10.1093/jcag/gwz035 10.1186/1741-7015-12-43 10.1136/annrheumdis-2015-207764 10.1136/annrheumdis-2015-208783 10.1136/annrheumdis-2016-eular.4143 10.1080/03007995.2019.1571296 10.1007/s00228-018-2418-4 10.1016/S1470-2045(16)30374-6 10.1016/S2468-1253(18)30082-7 10.1136/annrheumdis-2012-203090 10.1001/amajethics.2019.668 10.1038/nrgastro.2016.155 10.1136/annrheumdis-2017-211741 10.1097/MIB.0000000000000995 10.1016/j.dld.2019.02.004 10.1136/annrheumdis-2016-210742 10.1002/art.41201 10.1136/annrheumdis-2015-208786 10.1097/MIB.0000000000000886 10.1080/14397595.2016.1206244 10.1111/apt.14430 10.1093/jcag/gwz044 10.1111/bjd.16890 10.1093/ecco-jcc/jjv220 10.1111/apt.14997 10.1111/apt.15323 10.7326/M18-1512 10.1111/apt.13847 10.1056/NEJMp1504672 10.1016/S0140-6736(18)32196-2 10.1111/joim.12880 10.1182/blood-2014-06-583617 10.1111/jdv.14605 10.1111/apt.14030 10.1053/j.gastro.2018.03.002 10.1080/03007995.2018.1560221 10.1007/s10620-019-06036-0 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 by The American College of Gastroenterology. 2020 by The American College of Gastroenterology |
| Copyright_xml | – notice: Copyright © 2020 by The American College of Gastroenterology. – notice: 2020 by The American College of Gastroenterology |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.14309/ajg.0000000000000844 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Eastern Edition CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1572-0241 |
| EndPage | 56 |
| ExternalDocumentID | 10_14309_ajg_0000000000000844 33110013 |
| Genre | Journal Article Review |
| GeographicLocations | United States--US Europe |
| GeographicLocations_xml | – name: United States--US – name: Europe |
| GroupedDBID | --- 0R~ 123 23M 36B 39C 4.4 53G 5RE 6J9 70F 7X7 88E 8FI 8FJ 8GM AAAAV AAGIX AAHPQ AAIQE AAJCS AAMOA AAQKA AASCR AASXQ ABASU ABDIG ABJNI ABLJU ABOCM ABUWG ABVCZ ACGFO ACGFS ACILI ACKTT ACLDA ACNWC ACOAL ACXJB ADBBV ADFRT ADGGA ADHPY AEBDS AENEX AEXYK AFDTB AFEBI AFEXH AFKRA AFUWQ AGAYW AHMBA AHOMT AHQNM AHSBF AINUH AJIOK AJNWD AJRNO AJZMW AKRWK AKULP ALIPV ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW BENPR BPHCQ BVXVI BYPQX C45 CCPQU CGR CS3 CUY CVF DIWNM EBS ECM EE. EEVPB EIF EJD EMB ERAAH F5P FCALG FDB FDQFY FYUFA GNXGY GQDEL HLJTE HMCUK HZ~ IHE IKREB IKYAY IPNFZ JSO M1P NPM O9- ODMTH OPUJH OVD OVDNE P0W P2P PQQKQ PROAC PSQYO RIG RLZ RNT RNTTT SJN SNX TEORI TSPGW UKHRP XIF --K -Q- .55 .GJ 1B1 1OC 31~ 3O- 3V. 4G. 5VS AAEDT AALRI AAQFI AAQQT AAQXK AAXUO AAYOK AAYXX ABAWZ ACXQS ADMUD ADNKB AEETU AFBPY AFFNX AHVBC AI. AJAOE CAG CITATION COF EMOBN FEDTE FGOYB HVGLF LH4 LW6 M41 N4W NQ- R2- ROL RPZ SEW SSZ SV3 UDS VH1 X7M XPP ZGI ZXP ZZMQN 7XB 8FK K9. PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c403t-81c363458df6a85b450f107f75f3c98147a64f64bb54bf9dc70844755c4f5b6c3 |
| IEDL.DBID | BENPR |
| ISSN | 0002-9270 |
| IngestDate | Fri Oct 25 09:37:35 EDT 2024 Thu Oct 10 17:45:36 EDT 2024 Wed Oct 09 16:55:08 EDT 2024 Wed Oct 16 00:38:34 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Copyright © 2020 by The American College of Gastroenterology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c403t-81c363458df6a85b450f107f75f3c98147a64f64bb54bf9dc70844755c4f5b6c3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| PMID | 33110013 |
| PQID | 2507459964 |
| PQPubID | 2041977 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2455171019 proquest_journals_2507459964 crossref_primary_10_14309_ajg_0000000000000844 pubmed_primary_33110013 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-01 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: New York |
| PublicationTitle | The American journal of gastroenterology |
| PublicationTitleAlternate | Am J Gastroenterol |
| PublicationYear | 2021 |
| Publisher | Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins |
| Publisher_xml | – name: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins |
| References | Strik (R62-20241008) 2018; 3 Yu (R5-20241008) 2018; 47 Fiorino (R21-20241008) 2019; 51 Park (R15-20241008) 2013; 72 Meyer (R44-20241008) 2019; 50 Smolen (R32-20241008) 2018; 77 Tanaka (R33-20241008) 2017; 27 Glintborg (R58-20241008) 2017; 76 Feagan (R7-20241008) 2019; 49 Jorgensen (R34-20241008) 2017; 389 Moayyedi (R39-20241008) 2020; 3 Mehr (R51-20241008) 2019; 33 Blauvelt (R64-20241008) 2018; 179 Cholapranee (R1-20241008) 2017; 45 Weise (R14-20241008) 2014; 124 Ha (R48-20241008) 2016; 22 Yoo (R16-20241008) 2013; 72 Ye (R36-20241008) 2019; 393 Ilias (R40-20241008) 2019; 17 Greene (R57-20241008) 2019; 25 Sarpatwari (R6-20241008) 2015; 372 Morrow (R9-20241008) 2004; 1 Danese (R26-20241008) 2017; 14 Choe (R23-20241008) 2017; 76 Meyer (R35-20241008) 2019; 170 Kaplan (R43-20241008) 2020 Mao (R2-20241008) 2017; 45 Mocsai (R11-20241008) 2014; 12 Yoo (R18-20241008) 2017; 76 Brook (R56-20241008) 2018; 24 Schellekens (R8-20241008) 2016; 17 Kay (R27-20241008) 2015; 74 Kay (R29-20241008) 2015; 73 Teeple (R60-20241008) 2019; 35 Bernard (R41-20241008) 2020; 65 Röder (R38-20241008) 2018; 8 Kim (R53-20241008) 2020; 72 Zhai (R55-20241008) 2019; 21 Teeple (R61-20241008) 2019; 35 Boone (R63-20241008) 2018; 74 Park (R17-20241008) 2017; 76 Taylor (R28-20241008) 2016; 75 Gerdes (R65-20241008) 2018; 32 Goll (R37-20241008) 2019; 285 Fiorino (R31-20241008) 2017; 23 Gecse (R30-20241008) 2016; 10 Howden (R13-20241008) 2018; 154 |
| References_xml | – volume: 72 start-page: 1605 year: 2013 ident: R15-20241008 article-title: A randomized, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2012-203091 contributor: fullname: Park – volume: 17 start-page: 2506 year: 2019 ident: R40-20241008 article-title: Outcomes of patients with inflammatory bowel diseases switched from maintenance therapy with a biosimilar to Remicade publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2018.12.036 contributor: fullname: Ilias – volume: 389 start-page: 2304 year: 2017 ident: R34-20241008 article-title: Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomized, double-blind, non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(17)30068-5 contributor: fullname: Jorgensen – volume: 8 start-page: A456 year: 2018 ident: R38-20241008 article-title: Switch of infliximab originator to biosimilar CT-P13 in patients with Crohn's disease and ulcerative colitis in a large German IBD center. A one year, randomized and prospective trial (abstract) publication-title: United European Gastroenterol J contributor: fullname: Röder – volume: 24 start-page: s101 year: 2018 ident: R56-20241008 article-title: Management of specialty drugs, specialty pharmacies, and biosimilars in the United States publication-title: J Manag Care Spec Pharm contributor: fullname: Brook – volume: 3 start-page: e1 year: 2020 ident: R39-20241008 article-title: Joint Canadian Association of Gastroenterology and Crohn's Colitis Canada position statement on biosimilars for the treatment of inflammatory bowel disease publication-title: J Can Assoc Gastroenterol doi: 10.1093/jcag/gwz035 contributor: fullname: Moayyedi – volume: 12 start-page: 43 year: 2014 ident: R11-20241008 article-title: What is the future of targeted therapy in rheumatology: Biologics or small molecules? publication-title: BMC Med doi: 10.1186/1741-7015-12-43 contributor: fullname: Mocsai – volume: 76 start-page: 58 year: 2017 ident: R23-20241008 article-title: A randomized, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-207764 contributor: fullname: Choe – volume: 76 start-page: 346 year: 2017 ident: R17-20241008 article-title: Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-208783 contributor: fullname: Park – volume: 75 start-page: 488 issue: Suppl 2 year: 2016 ident: R28-20241008 article-title: FRI0163 Efficacy of the biosimilar BOW015, compared to originator infliximab, initiated at moderate and severe disease activity thresholds in rheumatoid arthritis publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2016-eular.4143 contributor: fullname: Taylor – volume: 35 start-page: 611 year: 2019 ident: R60-20241008 article-title: Physician attitudes about non-medical switching to biosimilars: Results from an online physician survey in the United States publication-title: Curr Med Res Opin doi: 10.1080/03007995.2019.1571296 contributor: fullname: Teeple – volume: 73 start-page: 462 issue: Suppl 2 year: 2015 ident: R29-20241008 article-title: FRI0117 BOW015, a biosimilar infliximab: Disease activity and disability outcomes from a phase 3 active comparator study in patients with active rheumatoid arthritis on stable methotrexate doses publication-title: Ann Rheum Dis contributor: fullname: Kay – volume: 74 start-page: 655 year: 2018 ident: R63-20241008 article-title: The nocebo effect challenges the non-medical infliximab switch in practice publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-018-2418-4 contributor: fullname: Boone – volume: 17 start-page: e502 year: 2016 ident: R8-20241008 article-title: Safety and efficacy of biosimilars in oncology publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30374-6 contributor: fullname: Schellekens – volume: 3 start-page: 404 year: 2018 ident: R62-20241008 article-title: Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): An open-label, multicentre, phase 4 non-inferiority trial publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(18)30082-7 contributor: fullname: Strik – volume: 72 start-page: 1613 year: 2013 ident: R16-20241008 article-title: A randomized, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2012-203090 contributor: fullname: Yoo – volume: 74 start-page: 1034 issue: Suppl 2 year: 2015 ident: R27-20241008 article-title: AB0420 secondary efficacy outcomes from a phase 3 study support clinical equivalence between BOW015 and infliximab in patients with active rheumatoid arthritis on stable methotrexate doses publication-title: Ann Rheum Dis contributor: fullname: Kay – volume: 21 start-page: E668 year: 2019 ident: R55-20241008 article-title: Why are biosimilars not living up to their promise in the US? publication-title: AMA J Ethics doi: 10.1001/amajethics.2019.668 contributor: fullname: Zhai – volume: 14 start-page: 22 year: 2017 ident: R26-20241008 article-title: Biosimilars in IBD: From theory to practice publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2016.155 contributor: fullname: Danese – volume: 77 start-page: 234 year: 2018 ident: R32-20241008 article-title: Safety, immunogenicity, and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: Results of a randomized, double-blind, phase III transition study publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2017-211741 contributor: fullname: Smolen – volume: 23 start-page: 233 year: 2017 ident: R31-20241008 article-title: The PROSIT-BIO cohort: A prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000000995 contributor: fullname: Fiorino – volume: 51 start-page: 632 year: 2019 ident: R21-20241008 article-title: Use of biosimilars in inflammatory bowel disease: A position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) publication-title: Dig Liver Dis doi: 10.1016/j.dld.2019.02.004 contributor: fullname: Fiorino – volume: 76 start-page: 1426 year: 2017 ident: R58-20241008 article-title: A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2016-210742 contributor: fullname: Glintborg – volume: 72 start-page: 1036 year: 2020 ident: R53-20241008 article-title: Utilization and treatment costs of tumor necrosis factor inhibitors after the introduction of biosimilar infliximab in the U.S. publication-title: Arthritis Rheumatol doi: 10.1002/art.41201 contributor: fullname: Kim – volume: 76 start-page: 355 year: 2017 ident: R18-20241008 article-title: Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-208786 contributor: fullname: Yoo – volume: 22 start-page: 2513 year: 2016 ident: R48-20241008 article-title: A critical review of biosimilars in IBD: The confluence of biologic drug development, regulatory requirements, clinical outcomes, and big business publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000000886 contributor: fullname: Ha – volume: 27 start-page: 237 year: 2017 ident: R33-20241008 article-title: Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab publication-title: Mod Rheumatol doi: 10.1080/14397595.2016.1206244 contributor: fullname: Tanaka – volume: 33 start-page: 1 year: 2019 ident: R51-20241008 article-title: Biosimilars in the USA: Will new efforts to Spur approvals and access Spur uptake and cost savings? publication-title: Pharmaceut Med contributor: fullname: Mehr – volume: 47 start-page: 364 year: 2018 ident: R5-20241008 article-title: Market share and costs of biologic therapies for inflammatory bowel disease in the USA publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.14430 contributor: fullname: Yu – year: 2020 ident: R43-20241008 article-title: The argument against a biosimilar switch policy for infliximab in patients with inflammatory bowel disease living in Alberta publication-title: J Can Assoc Gastroenterol doi: 10.1093/jcag/gwz044 contributor: fullname: Kaplan – volume: 179 start-page: 623 year: 2018 ident: R64-20241008 article-title: Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: Impact of multiple switches publication-title: Br J Dermatol doi: 10.1111/bjd.16890 contributor: fullname: Blauvelt – volume: 10 start-page: 133 year: 2016 ident: R30-20241008 article-title: Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: A prospective, multicentre, nationwide cohort publication-title: J Crohns Colitis doi: 10.1093/ecco-jcc/jjv220 contributor: fullname: Gecse – volume: 25 start-page: 904 year: 2019 ident: R57-20241008 article-title: Strategies for overcoming barriers to adopting biosimilars and achieving goals of the biologics price competition and innovation Act: A survey of managed care and specialty pharmacy professionals publication-title: J Manag Care Spec Pharm contributor: fullname: Greene – volume: 49 start-page: 31 year: 2019 ident: R7-20241008 article-title: Systematic review: Efficacy and safety of switching patients between reference and biosimilar infliximab publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.14997 contributor: fullname: Feagan – volume: 50 start-page: 269 year: 2019 ident: R44-20241008 article-title: The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.15323 contributor: fullname: Meyer – volume: 170 start-page: 99 year: 2019 ident: R35-20241008 article-title: Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: A French equivalence study publication-title: Ann Intern Med doi: 10.7326/M18-1512 contributor: fullname: Meyer – volume: 45 start-page: 3 year: 2017 ident: R2-20241008 article-title: Systematic review with meta-analysis: Comparative efficacy of immunosuppressants and biologics for reducing hospitalization and surgery in Crohn's disease and ulcerative colitis publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13847 contributor: fullname: Mao – volume: 372 start-page: 2380 year: 2015 ident: R6-20241008 article-title: Progress and hurdles for follow-on biologics publication-title: N Engl J Med doi: 10.1056/NEJMp1504672 contributor: fullname: Sarpatwari – volume: 1 start-page: 24 year: 2004 ident: R9-20241008 article-title: Defining the difference: What makes biologics unique publication-title: Biotechnol Healthc contributor: fullname: Morrow – volume: 393 start-page: 1699 year: 2019 ident: R36-20241008 article-title: Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: An international, randomized, double-blind, phase 3 non-inferiority study publication-title: Lancet doi: 10.1016/S0140-6736(18)32196-2 contributor: fullname: Ye – volume: 285 start-page: 653 year: 2019 ident: R37-20241008 article-title: Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial publication-title: J Intern Med doi: 10.1111/joim.12880 contributor: fullname: Goll – volume: 124 start-page: 3191 year: 2014 ident: R14-20241008 article-title: Biosimilars: The science of extrapolation publication-title: Blood doi: 10.1182/blood-2014-06-583617 contributor: fullname: Weise – volume: 32 start-page: 420 year: 2018 ident: R65-20241008 article-title: Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.14605 contributor: fullname: Gerdes – volume: 45 start-page: 1291 year: 2017 ident: R1-20241008 article-title: Systematic review with meta-analysis: Comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.14030 contributor: fullname: Cholapranee – volume: 154 start-page: e1 year: 2018 ident: R13-20241008 article-title: Meeting report: AGA biosimilars roundtable publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.03.002 contributor: fullname: Howden – volume: 35 start-page: 603 year: 2019 ident: R61-20241008 article-title: Patient attitudes about non-medical switching to biosimilars: Results from an online patient survey in the United States publication-title: Curr Med Res Opin doi: 10.1080/03007995.2018.1560221 contributor: fullname: Teeple – volume: 65 start-page: 2354 year: 2020 ident: R41-20241008 article-title: Systemic review: Non-medical switching of infliximab to CT-P13 in inflammatory bowel disease publication-title: Dig Dis Sci doi: 10.1007/s10620-019-06036-0 contributor: fullname: Bernard |
| SSID | ssj0015275 |
| Score | 2.4658384 |
| SecondaryResourceType | review_article |
| Snippet | Over the past 2 decades, biological therapy with monoclonal antibodies targeting tumor necrosis factor-α has become a cornerstone of treatment of patients with... |
| SourceID | proquest crossref pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 45 |
| SubjectTerms | Adalimumab - economics Adalimumab - therapeutic use Autoimmune diseases Biological products Biosimilar Pharmaceuticals - economics Biosimilar Pharmaceuticals - therapeutic use Drug Costs Drug Substitution FDA approval Gastroenterology Health Expenditures Health Services Accessibility Humans Inflammatory bowel disease Inflammatory Bowel Diseases - drug therapy Infliximab - economics Infliximab - therapeutic use Pharmacokinetics Regulatory approval Tumor Necrosis Factor Inhibitors - therapeutic use Tumor necrosis factor-TNF |
| Title | Biosimilars in Inflammatory Bowel Disease |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33110013 https://www.proquest.com/docview/2507459964 https://search.proquest.com/docview/2455171019 |
| Volume | 116 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1NS8QwEB10BfEifrt-LBW8eKh2m0nSnMRVFxUUEYW9laRtZEVbdVf8-0626YqC9lZaWvJmyLzJS2YA9g1TPLJahjzHOETNVWgoLIWaU7AnuqsS6w4nX9-Iiwe8GvCBX3Ab-W2VzZw4majzKnNr5EcUqiW6WiJ4_PoWuq5RTl31LTRmYS6mTCFqwVzv_Ob2bqoj8FjyhgCrWEb-DA-ySB3pp8e6emFzJYg_o9MflHMSevpLsOg5Y3BSG3kZZopyBeavvSq-Cge9YTUavgxdkhoMy-CytGTnl4l-HvSqz-I5OKt1mDV46J_fn16EvgVCmGHExmHSzZhgyJPcCp1wgwQsJWxWcssylXRRaoFWoDEcjVV5Jt0oJOcZWm5ExtahVVZlsQlBLnTGRW7z2BZoikJT_ki3MomEorBv23DYDD19rStdpC5DcFilhFX6G6s27DQApd7xR-m3mdqwN31MLut0CF0W1Qe9g0TTiNl0VRs2amCnf2TM1bDrsq3_P74NC7HbXDJZC9mB1vj9o9gldjA2HZiVA9nxjvAFW9G0TA |
| link.rule.ids | 315,783,787,12068,21400,27936,27937,31731,31732,33756,33757,43322,43817,74073,74630 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLZgSMAF8WYwoEhcOJR1i5M0J8Rr2mDbaZN2q5K2QUOsHWwTf5-kjyGQoLeqVat8tvJ9jhMb4FIRQT0tuUsjbLooqXCVoSVXUkP2Ru4KX9vDyb0-aw_xaURHxYLbrNhWWc6J2UQdpaFdI68bquZoa4ngzfTdtV2jbHa1aKGxCmu2DpftYMBHy4DLdmylpfwVTe4VJ3iQeKIuX1_y2oXl5SP-5KY_BGdGPK1t2CoUo3Obm3gHVuJkF9Z7RU58D67uxulsPBnbENUZJ04n0cbKkyx77tyln_Gb85BnYfZh2Hoc3LfdogGCG6JH5q7fCAkjSP1IM-lThQZWE65pTjUJhd9ALhlqhkpRVFpEIbej4JSGqKliITmASpIm8RE4EZMhZZGOmjpGFcfSRI_mlvseE4b0dRWuy6EH07zORWDjA4tVYLAKfmNVhVoJUFC4_Sz4NlIVLpaPjcPaLIRM4nRh3kEj0oyuaYgqHObALv9IiK1g1yDH_3_8HDbag1436Hb6zyew2bTbTLJVkRpU5h-L-NTohLk6y5zhC5mPtPA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fj9MwDLZgkyZeEL_u2DGgSPdyD711jZM0T4hxmzZg04Ru0t6qpG1OQ6zdsU38-zhrOgQS9K1q1Cq2G3_O59gAl4YpHlktQ55jHKLmKjTklkLNydkT3FWJdYeTZ3MxWeKnFV_5_KedT6ts1sTjQp1Xmdsj75OrluhqiWDf-rSIxc34_fY-dB2kHNPq22k8hLZEwaIWtIej-eLriVPgseQNGFaxjPx5HmSR6utvd3Ulw-ZKEP_0VP-An0c3NH4Cjz1-DD7UCn8KD4ryGXRmniF_DlfDdbVbb9YuYA3WZTAtLel8c-TSg2H1s_ge3NSczAtYjke3Hyehb4cQZhixfZgMMiYY8iS3QifcIAmZgjcruWWZSgYotUAr0BiOxqo8k24WkvMMLTciY2fQKquyeAlBLnTGRW7z2BZoikJTLEm3MomEIghgu3DdTD3d1lUvUhctOFmlJKv0b1l1odcIKPU_wS79rbIuvDs9JvN1nIQui-pAY5AgG6GcgerCeS3Y0xcZc_XsBuzi_y9_Cx2yhPTLdP75FTyKXc7JcYukB639j0PxmkDD3rzx1vALa-S6jQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Biosimilars+in+Inflammatory+Bowel+Disease&rft.jtitle=The+American+journal+of+gastroenterology&rft.au=Buchner%2C+Anna+M&rft.au=Schneider%2C+Yecheskel&rft.au=Lichtenstein%2C+Gary+R&rft.date=2021-01-01&rft.eissn=1572-0241&rft.volume=116&rft.issue=1&rft.spage=45&rft.epage=56&rft_id=info:doi/10.14309%2Fajg.0000000000000844&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9270&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9270&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9270&client=summon |